Key points are not available for this paper at this time.
To address ongoing concerns about the implementation of the FDA’s Accelerated Approval pathway in oncology, a comprehensive strategy is needed — one that equally emphasizes “on-ramp” and “off-ramp” considerations.
Fashoyin‐Aje et al. (Wed,) studied this question.